Manitoba Protein Consortium, to provide leadership on projects of strategic importance and encourage stakeholders to continue actions to implement the Manitoba Protein Advantage strategy.
Eleven Biotherapeutics, Inc. is a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents based on our Targeted Protein Therapeutics (TPTs) platform. Our TPTs genetically combine targeting antibody fragments with cytoxic protein payloads to create a single fusion protein through Eleven's proprietary one-step manufacturing process.
We have designed TPTs with the potential to offer:
- Multiple advantages in treating cancer over traditional antibody drug conjugates.
- Effective tumor targeting with cancer cell-killing properties unique to protein payloads versus small molecules, using our rational approach to therapeutics design for TPTs.
- The dual action of the TPT protein cytotoxic to both kill directly and promote a local inflammatory anti-tumor immune response, suggesting that TPTs will combine well with immune oncology drugs.
- Enhanced linker stability and more efficient and cost effective manufacturing process, based on TPT’s fusion protein construction.